Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29


Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials.

Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, Mullane KM, Kotton C, Lundgren J, Komatsu TE, Lischka P, Josephson F, Douglas CM, Umeh O, Miller V, Ljungman P; Resistant Definitions Working Group of the Cytomegalovirus Drug Development Forum.

Clin Infect Dis. 2019 Apr 8;68(8):1420-1426. doi: 10.1093/cid/ciy696.


Mutual Interplay between the Human Cytomegalovirus Terminase Subunits pUL51, pUL56, and pUL89 Promotes Terminase Complex Formation.

Neuber S, Wagner K, Goldner T, Lischka P, Steinbrueck L, Messerle M, Borst EM.

J Virol. 2017 May 26;91(12). pii: e02384-16. doi: 10.1128/JVI.02384-16. Print 2017 Jun 15.


Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir.

Lischka P, Zhang D, Holder D, Zimmermann H.

Antiviral Res. 2016 Aug;132:204-9. doi: 10.1016/j.antiviral.2016.06.008. Epub 2016 Jun 23.


Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228).

Lischka P, Michel D, Zimmermann H.

J Infect Dis. 2016 Jan 1;213(1):23-30. doi: 10.1093/infdis/jiv352. Epub 2015 Jun 25.


In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication.

Wildum S, Zimmermann H, Lischka P.

Antimicrob Agents Chemother. 2015;59(6):3140-8. doi: 10.1128/AAC.00114-15. Epub 2015 Mar 16.


Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation.

Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhäuser M, Groth C, Einsele H, Silverman M, Mullane KM, Brown J, Nowak H, Kölling K, Stobernack HP, Lischka P, Zimmermann H, Rübsamen-Schaeff H, Champlin RE, Ehninger G; AIC246 Study Team.

N Engl J Med. 2014 May 8;370(19):1781-9. doi: 10.1056/NEJMoa1309533.


Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure.

Goldner T, Hempel C, Ruebsamen-Schaeff H, Zimmermann H, Lischka P.

Antimicrob Agents Chemother. 2014;58(1):610-3. doi: 10.1128/AAC.01794-13. Epub 2013 Nov 4.


Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study.

Stoelben S, Arns W, Renders L, Hummel J, Mühlfeld A, Stangl M, Fischereder M, Gwinner W, Suwelack B, Witzke O, Dürr M, Beelen DW, Michel D, Lischka P, Zimmermann H, Rübsamen-Schaeff H, Budde K.

Transpl Int. 2014 Jan;27(1):77-86. doi: 10.1111/tri.12225. Erratum in: Transpl Int. 2014 Apr;27(4):416.


Nucleocytoplasmic shuttling and CRM1-dependent MHC class I peptide presentation of human cytomegalovirus pp65.

Frankenberg N, Lischka P, Pepperl-Klindworth S, Stamminger T, Plachter B.

Med Microbiol Immunol. 2012 Nov;201(4):567-79. doi: 10.1007/s00430-012-0269-7. Epub 2012 Sep 11.


In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses.

Marschall M, Stamminger T, Urban A, Wildum S, Ruebsamen-Schaeff H, Zimmermann H, Lischka P.

Antimicrob Agents Chemother. 2012 Feb;56(2):1135-7. doi: 10.1128/AAC.05908-11. Epub 2011 Nov 21.


The cellular DExD/H-box RNA-helicases UAP56 and URH49 exhibit a CRM1-independent nucleocytoplasmic shuttling activity.

Thomas M, Lischka P, Müller R, Stamminger T.

PLoS One. 2011;6(7):e22671. doi: 10.1371/journal.pone.0022671. Epub 2011 Jul 22.


The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase.

Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P.

J Virol. 2011 Oct;85(20):10884-93. doi: 10.1128/JVI.05265-11. Epub 2011 Jul 13.


First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246.

Kaul DR, Stoelben S, Cober E, Ojo T, Sandusky E, Lischka P, Zimmermann H, Rubsamen-Schaeff H.

Am J Transplant. 2011 May;11(5):1079-84. doi: 10.1111/j.1600-6143.2011.03530.x.


Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor.

Sukla S, Biswas S, Birkmann A, Lischka P, Zimmermann H, Field HJ.

J Antimicrob Chemother. 2010 Jul;65(7):1347-52. doi: 10.1093/jac/dkq135. Epub 2010 May 7.


Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant.

Sukla S, Biswas S, Birkmann A, Lischka P, Ruebsamen-Schaeff H, Zimmermann H, Field HJ.

Antiviral Res. 2010 Jul;87(1):67-73. doi: 10.1016/j.antiviral.2010.04.008. Epub 2010 Apr 24.


In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246.

Lischka P, Hewlett G, Wunberg T, Baumeister J, Paulsen D, Goldner T, Ruebsamen-Schaeff H, Zimmermann H.

Antimicrob Agents Chemother. 2010 Mar;54(3):1290-7. doi: 10.1128/AAC.01596-09. Epub 2010 Jan 4.


Inhibition of human cytomegalovirus replication via peptide aptamers directed against the nonconventional nuclear localization signal of the essential viral replication factor pUL84.

Kaiser N, Lischka P, Wagenknecht N, Stamminger T.

J Virol. 2009 Nov;83(22):11902-13. doi: 10.1128/JVI.01378-09. Epub 2009 Sep 9.


Antiviral strategies to combat cytomegalovirus infections in transplant recipients.

Lischka P, Zimmermann H.

Curr Opin Pharmacol. 2008 Oct;8(5):541-8. doi: 10.1016/j.coph.2008.07.002. Epub 2008 Aug 25. Review.


Multimerization of human cytomegalovirus regulatory protein UL69 via a domain that is conserved within its herpesvirus homologues.

Lischka P, Thomas M, Toth Z, Mueller R, Stamminger T.

J Gen Virol. 2007 Feb;88(Pt 2):405-10.


Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina.

Marschall M, Marzi A, aus dem Siepen P, Jochmann R, Kalmer M, Auerochs S, Lischka P, Leis M, Stamminger T.

J Biol Chem. 2005 Sep 30;280(39):33357-67. Epub 2005 Jun 23.


HIV-1 Nef mimics an integrin receptor signal that recruits the polycomb group protein Eed to the plasma membrane.

Witte V, Laffert B, Rosorius O, Lischka P, Blume K, Galler G, Stilper A, Willbold D, D'Aloja P, Sixt M, Kolanus J, Ott M, Kolanus W, Schuler G, Baur AS.

Mol Cell. 2004 Jan 30;13(2):179-90.


Structural requirements for nuclear localization of GCMa/Gcm-1.

Hashemolhosseini S, Kilian K, Kardash E, Lischka P, Stamminger T, Wegner M.

FEBS Lett. 2003 Oct 23;553(3):315-20.


Sox10 is an active nucleocytoplasmic shuttle protein, and shuttling is crucial for Sox10-mediated transactivation.

Rehberg S, Lischka P, Glaser G, Stamminger T, Wegner M, Rosorius O.

Mol Cell Biol. 2002 Aug;22(16):5826-34.

Supplemental Content

Loading ...
Support Center